prenetics.com (PRE) - Long-Term Debt to Capital Ratio

Corporate emblem and logo of Prenetics Global Limited (PRE)

Prenetics Global (PRE) is a leading player in the Asian genomic research market, offering affordable DNA tests and digital services for early diagnosis. The company is currently optimizing expenses and focusing on the organic growth of its software, while the price action shown below reflects a value of 0.00. Business stability is underpinned by centers in the UK and Hong Kong that implement advanced methods of preventive medicine.

Prenetics (PRE): Long-Term Debt to Equity from 04/28/2023 to 10/29/2026

Analytical breakdowns for Prenetics Global

- market price and analyst price targets:
Market Price Prenetics Global Ltd|PRE - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Prenetics Global|PRE - Enterprise Value
- issuer book value statistics:
Book Value per Share Prenetics|PRE - Company Book Value|Capitalization to Book Value Ratio prenetics.com|PRE - Company Total Assets
- debt and solvency information:
Total Debt to Capital Prenetics Global|PRE - Long-Term Debt to Equity|Short-Term Debt to Equity Prenetics Global Ltd|PRE - Company Total Debt|Debts to Book Value Prenetics Global|PRE - Company Long-Term Debt|Short-Term Debt Volume Prenetics|Interim Coverage Ratio prenetics.com
- net income and valuation ratios data:
PRE - Company Net Income
General company analysis:PRE (prenetics.com)
Core merchandise of Prenetics Global Ltd

Prenetics Global's development in personalized medicine and genetics requires significant capital expenditures in diagnostic technologies and the expansion of its Asian network. The dynamics of the long-term debt-to-equity ratio reflect the proportion between long-term liabilities and the market value of shares, demonstrating the balance of interests between creditors and business owners. A decrease in this metric may indicate either financial stability or a stagnation of investment in expansion.

Analysis of competing companies

Long-Term Liabilities to Capital Agilent Technologies, Inc. A|Long-Term Debt to Capital DGX|Illumina Platform - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital EXAS (Exact Sciences)|Long-Term Debt to Capital revvity.com RVTY|BIO - Long-Term Debt to Equity|NNNN (Anbio Biotechnology Ltd) - Long-Term Debt to Capital Ratio|SHC: Long-Term Debt to Capital|QuidelOrtho Inc. (QDEL) - Long-Term Debt to Capital|Long-Term Debt to Equity OPKO Health, Inc.|Long-Term Debt to Equity CDNA|Long-Term Debt to Equity Ratio MRVI (Maravai LifeSciences Holdings, Inc.)|FLGT - Long-Term Liabilities to Capital|Long-Term Debt to Equity Fluidigm LAB|Ratio of Long-Term Indebtedness to Capital Cytek Corp (CTKB)|OraSure Technologies - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Exagen Inc. XGN|MDxHealth (MDXH) - Long-Term Debt to Equity|LUCD - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Insight Molecular Diagnostics, Inc.|Trinity Biotech Corp - Long-Term Liabilities to Equity|Long-Term Debt to Equity ProPhase Labs, Inc. (PRPH)|AIMD (ainos.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital CODX (Co-Diagnostics)|Heart Test Laboratories, Inc. (HSCS) - Long-Term Liabilities to Capital|BMRA - Long-Term Debt to Equity|CDIO (Cardio Diagnostics) - Long-Term Debt to Capital Ratio|VRAX: Long-Term Debt to Capital|Long-Term Liabilities to Capital bluejaydx.com (BJDX)|Long-Term Debt to Equity Ratio AWH|AXDX (Accelerate Diagnostics Inc.) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital CNTG|Ratio of Long-Term Indebtedness to Capital enzo.com|Long-Term Debt to Capital FRES (Fresh2 Group)|GENE - Long-Term Debt to Equity Ratio|ME - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Psychemedics Corp. PMD